Reply #301: I don't trust anything Chem/Pharm says. Iatrogenic deaths are extremely high in this country

[AikidoSoul]

with over 125,000 persons dying from prescription drugs alone -- while in hospital. That is widely believed to be under-reported, although several "mainstrem" medical societies like to publish lower numbers. There are no figures for those who die from drugs while not in hospital. Add to that the aggressive and well-financed denials from the chem/pharm industry for damage caused by many of its products.

The Review entitled, "Vaccination and autoimmune disease: what is the evidence?" mentions as if in passing, the fact that "environment" plays a role in autoimmune disease, but it only emphasizes infection, and does not even mention toxic chemicals.

They don't mention that toxicant triggers for autoimmune diseases are researched by others. More specifically by those who do not have direct links to chem/pharm industry.

If you note the Conflict of interest statement at the end of the article you will note the authors are connected to the chem/ pharm industry:

M Goldman has served as a consultant for Aventis-Pasteur, BruCells,

Glaxo SmithKline, and OM-Pharma. P-H Lambert has served as a

consultant for Aventis-Pasteur, Chiron, Glaxo SmithKline, and

OM-Pharma. D Wraith is a director of Apitope Technology (Bristol), and

has served as consultant for Glaxo SmithKline, Peptide Therapeutics, and

Teva Pharmaceutical Industries.

*******************

There was brief mention in the review of "adjuvants" in vaccines, but no mention of the fact that many of them are implicated in chronic illnesses. If one does a thorough search of the med/ sci and legal literature -- you will see that this industry plays an aggressive role in suppressing information about how its vaccines, including its preservatives and "adjuvants" -- are judged. Many drugs contain toxic chemicals and adjuvants. Woe to those who declare them unsafe, and/or highly suspect. Those who do so are usually researchers outside the industry, who then find their careers on the short end.